Kuehn Law Encourages Investors of Kyndryl Holdings, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Kyndryl Holdings breached fiduciary duties by manipulating free cash flow metrics through delayed vendor payments and misrepresenting the sustainability of earnings. The firm alleges inadequate financial disclosure procedures and internal controls, and that the company's actual financial condition and growth prospects were materially worse than publicly represented.

06/17/2026, 10:18 PM • GlobeNewswire

Arnhold LLC Bets Big on Kyndryl Holdings (KD) With a Purchase of 724,000 Shares

Arnhold LLC increased its stake in Kyndryl Holdings by 724,436 shares (60% increase) for approximately $12.75 million during Q1 2026. Despite the purchase, the position's value declined by $6.60 million due to the stock's 69% drop over the past year. The analyst suggests Arnhold's confidence appears misplaced given Kyndryl's stagnant revenue and contracting bottom line.

05/28/2026, 3:25 PM • The Motley Fool

Why Kyndryl Holdings Stock Dropped Today

Kyndryl Holdings stock fell 9.4% after missing Q4 2026 earnings expectations with $0.08 EPS versus expected $0.49 and sales of $3.8B versus expected $4B. Despite the miss, the company maintains strong free cash flow of $406M and projects $400-500M for fiscal 2027, leading the analyst to view the selloff as an overreaction.

05/06/2026, 1:34 PM • The Motley Fool

KYNDRYL DEADLINE: ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Kyndryl Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action First Filed by the Firm – KD

Rosen Law Firm reminds investors who purchased Kyndryl Holdings securities between August 7, 2024 and February 9, 2026 of the April 13, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Kyndryl made false statements regarding its financial condition, internal controls, and ability to file timely quarterly reports, resulting in investor losses.

04/10/2026, 10:29 PM • GlobeNewswire

INVESTOR DEADLINE: Kyndryl (KD) Investors with Substantial Losses Have Opportunity to Lead the Kyndryl Class Action Lawsuit– Hagens Berman

Hagens Berman has filed an expanded securities class action against Kyndryl Holdings (KD) alleging the company manipulated free cash flow metrics through undisclosed cash management practices to mask its true financial health. The lawsuit covers investors from August 1, 2024, to February 6, 2026. Following disclosure of an SEC investigation and the departure of the CFO and General Counsel on February 9, 2026, Kyndryl's stock plummeted 55% from $23.49 to $10.59 per share. The lead plaintiff deadline is April 13, 2026.

04/10/2026, 1:56 PM • GlobeNewswire

INVESTOR DEADLINE: Kyndryl (KD) Investors with Substantial Losses Have Opportunity to Lead the Kyndryl Class Action Lawsuit– Hagens Berman

Hagens Berman has filed an expanded securities class action against Kyndryl Holdings for allegedly manipulating free cash flow metrics through undisclosed cash management practices to mask financial weakness. The lawsuit covers investors from August 1, 2024 to February 6, 2026. Following an SEC investigation disclosure and executive departures on February 9, 2026, Kyndryl's stock plummeted 55% from $23.49 to $10.59 per share. The lead plaintiff deadline is April 13, 2026.

04/08/2026, 4:53 PM • GlobeNewswire

Deadline Alert: Kyndryl Holdings, Inc. (KD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Kyndryl Holdings, Inc. on behalf of investors who purchased securities between August 1, 2024 and February 9, 2026. The lawsuit alleges that Kyndryl made materially false statements and failed to disclose material adverse facts about its business, including misstated financial statements, inadequate internal controls, and inability to timely file quarterly reports. The company's stock fell 54.9% on February 9, 2026 following announcements of executive departures and SEC enforcement inquiries. The deadline to file a lead plaintiff motion is April 13, 2026.

04/07/2026, 7:28 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyndryl Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – KD

Pomerantz Law Firm has filed class action lawsuits against Kyndryl Holdings, AMC Entertainment, and NuScale Power Corporation. Kyndryl faced a 55% stock price drop following disclosure of an SEC investigation into financial reporting and the departure of its CFO, General Counsel, and Global Controller. Investors with losses are urged to contact the firm by April 13, 2026, to potentially become lead plaintiffs.

04/07/2026, 3:45 PM • GlobeNewswire

DEADLINE ALERT for PSFE, INO, KD: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against three publicly-traded companies: Paysafe Limited (PSFE) for undisclosed business risks and overstated guidance, Inovio Pharmaceuticals (INO) for deficient manufacturing and overstated regulatory prospects, and Kyndryl Holdings (KD) for misstated financial statements and inadequate internal controls. Lead plaintiff deadlines range from April 7-13, 2026.

04/07/2026, 12:00 PM • GlobeNewswire

KD Investors Have Opportunity to Lead Kyndryl Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased Kyndryl Holdings securities between August 7, 2024 and February 9, 2026 to join a class action lawsuit alleging securities fraud. The lawsuit claims Kyndryl made false and misleading statements, materially misstated financial statements, and failed to maintain adequate internal controls over financial reporting.

04/06/2026, 10:00 AM • GlobeNewswire

RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

Rosen Law Firm has filed securities class action lawsuits against Ultragenyx Pharmaceutical, Kyndryl Holdings, and Vital Farms, urging investors with significant losses to secure legal counsel before upcoming deadlines. The Ultragenyx case alleges the company made misleading statements about setrusumab's effectiveness in treating Osteogenesis Imperfecta, claiming bone density increases did not correlate to reduced fracture rates as promised.

04/05/2026, 6:37 PM • GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Kyndryl Holdings, Inc. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action First Filed by the Firm – KD

Rosen Law Firm is urging investors who purchased Kyndryl Holdings securities between August 7, 2024 and February 9, 2026 to join a securities class action lawsuit. The lawsuit alleges that Kyndryl made false statements about its financial condition, lacked adequate internal controls, and was unable to timely file its quarterly report for Q4 2025. The deadline to serve as lead plaintiff is April 13, 2026.

04/05/2026, 6:28 PM • GlobeNewswire

KD 9-DAY DEADLINE ALERT: Kyndryl (KD) Facing Securities Class Action Amid 55% Stock Drop After Four Bombshell Disclosures – Hagens Berman

Hagens Berman has filed an expanded securities class action against Kyndryl Holdings for allegedly manipulating free cash flow metrics to conceal true financial condition. The company's stock plummeted 55% following disclosure of an SEC investigation into cash management practices and the departure of its CFO and General Counsel on February 9, 2026. Investors have until April 13, 2026, to move for Lead Plaintiff status.

04/04/2026, 11:21 AM • GlobeNewswire

Deadline Alert: Kyndryl Holdings, Inc. (KD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Kyndryl Holdings faces a securities fraud class action lawsuit after the company announced on February 9, 2026 that its CFO and General Counsel departed immediately, it cannot timely file its quarterly report, and it is under SEC investigation regarding cash management practices and internal controls. The stock fell 54.9% on the news. Investors have until April 13, 2026 to file a lead plaintiff motion.

04/03/2026, 12:41 PM • GlobeNewswire

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026

Kirby McInerney LLP has filed securities fraud class action lawsuits against ImmunityBio, Kyndryl Holdings, and Super Micro Computer on behalf of investors. ImmunityBio faces allegations that Executive Chairman Patrick Soon-Shiong materially overstated capabilities of its Anktivas immunotherapy product. The FDA issued a warning letter on March 24, 2026, stating the company's marketing materials were false or misleading, causing ImmunityBio's stock to decline 21.2%. Investors have until specified deadlines to request lead plaintiff appointment.

04/02/2026, 8:00 PM • GlobeNewswire